pricing
Underwritten In Our Genes
October 05 by Tom MacfarlaneOne of the more creative responses to the US firearms debate, a response currently circulating social media with no easily identifiable origin, is to retain the right to bear arms whilst simulta...
Orphan Drugs – Reinventing Economies of Scale
November 16 by Cristina FalcãoEconomies of scale come in many flavors. Including the oddity flavor where the number of manufactured products decreases and the size of markets shrink. Orphan drugs are economies of scale’...
Are Orphan Drugs Still a Licence to Print Money?
July 20 by Andrea CharlesIn this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fun...
Russia: Localisation vs. Isolation - Part Two
February 08 by Cyrus ChowdhuryPharma2020 – Towards Self-Reliance or the WTO? In late 2008, The Russian Federation’s Ministry of Industry and Trade announced the Pharma2020 strategy as part of the Healthcare Develo...
Russia: Localisation vs. Isolation - Part One
February 03 by Cyrus ChowdhuryThe Rise of Russia: Not Just a BRIC Anymore Five years ago, few pharmaceutical executives would have believed that 2011 would bring a feverish scramble to invest in Russia. At the time, many beli...
Das Arzneimittelsparpaket: Wie kann sich die Pharmaindustrie auf die neuen Rahmenbedingungen einstellen?
July 28 by Pharma IQIn this Pharma IQ podcast, Isabel Henkel, Director, Access & Reimbursement at Johnson & Johnson Medical, talks about how the pharma industry needs to adjust to the new requirements of the...
6 Key Predictors of Outsourcing Success in a Maturing RE & FM Outsourcing Market
July 20 by Pharmaceuticals & Biotechnology EditorThis article will focus on critical RE & FM outsourcing success factors in the context of a dynamic and rapidly maturing global RE & FM supplier market. We will highlight how companies can c...
EU Price-Cut Pandemic: Managing with Discipline
July 01 by Cyrus ChowdhuryRecent weeks have revealed the immediate result of the European debt crisis: adoption of austerity measures, many of which prioritise an easy target, pharmaceutical expenditure. Governments tend...